The financials
Becton Dickinson by the numbers
Becton Dickinson (BDX) reported revenue of $4.98B in Q3 2026 (quarter ended June 30, 2026), up 5.4% from the same quarter a year earlier. That came with a gross margin of 46% and net income of $377M (7.6% of revenue). For the full year FY2025, revenue was $21.8B (+8.2% year on year) and net income $1.68B. Its largest segment in 2026-Q2 was Connected Care at $737M, 38% of the disclosed total, just ahead of Medical Essentials at 37%.
| Income statement | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Revenue | $4.98B | $4.73B | +5.4% |
| Gross profit | $2.31B | $2.23B | +3.6% |
| Operating income | $663M | $739M | −10% |
| Net income | $377M | $574M | −34% |
| Diluted EPS | $1.37 | $2.00 | −31% |
| Operating | Revenue | Share |
|---|---|---|
| Connected Care | $737M | 38% |
| Medical Essentials | $720M | 37% |
| Interventional | $294M | 15% |
| Bio Pharma Systems | $204M | 10% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2026Total $1.96B (+6.9%)
Bio Pharma Systems grew +15% year on yearConnected Care +3.9% year on year
Segment Latestquarter on quarteryear on year
- Connected Care$737.0M$737.0MQoQ +12%year on year +3.9%+12%+3.9%
- Medical Essentials$720.0M$720.0MQoQ +1.1%year on year +5.9%+1.1%+5.9%
- Interventional$294.0M$294.0MQoQ +5.4%year on year +8.5%+5.4%+8.5%
- Bio Pharma Systems$204.0M$204.0MQoQ +15%year on year +15%+15%+15%
- Life Sciences--QoQ -year on year ---
- Medical--QoQ -year on year ---
Medical Instruments & Supplies
Ranks #17 of 27 by Smart Score